Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
1 evidence topic · 5 sources
Summary
Current treatment is heterogeneous and frequently involves several antiseizure medications. The SCN8A caregiver survey found that 77% were taking at least two ASMs and 50% had tried and stopped at least four. Sodium channel blocker recommendations depend on variant function and phenotype: consensus guidance favors them in SCN8A gain-of-function disease but relatively contraindicates them in loss-of-function disease. In SCN2A epilepsy, later-onset disease was associated with less benefit and occasional seizure worsening. The cenobamate evidence cited here is a 12-participant observational series, not a randomized comparison with relutrigine.